Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Next Previous
Drug Profile

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: Anti-PD-L1 monoclonal antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; APL 502; CBT-502; PD-L1 antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group​; TQ-B2450

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apollomics; Crown Bioscience
  • Developer Apollomics; Chia Tai Tianqing Pharmaceutical Group; Chinese Academy of Medical Sciences; Fudan University; Shandong Cancer Hospital and Institute; Shanghai Tenth Peoples Hospital; The First Affiliated Hospital of Zhengzhou University; Zhengda Tianqing Pharmaceutical Group Co., Ltd.
  • Class Antineoplastics; Immunoglobulin isotypes; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Small cell lung cancer
  • Phase II Diffuse large B cell lymphoma; Endometrial cancer; Gynaecological cancer; Hepatitis B; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Squamous cell cancer
  • Phase I/II Acral lentiginous melanoma; Cholangiocarcinoma
  • Phase I Solid tumours
  • No development reported Triple negative breast cancer

Most Recent Events

  • 25 Jan 2024 Chia Tai Tianqing Pharmaceutical and Peking University plans a phase II trial for Gastric-cancer and Oesophageal-cancer in China (IV) in February 2024 (NCT06222944)
  • 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Biliary cancer presented at the Gastrointestinal Cancers Symposium (GICS-2024)
  • 18 Jan 2024 Efficacy and adverse events data from a phase II ALTER-E005 trial in Squamous cell cancer presented at the 2024 Gastrointestinal Cancers Symposium Session
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top